These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23473771)

  • 1. Level of HER2/neu amplification in primary tumours and metastases in HER2-positive breast cancer and survival after trastuzumab therapy.
    Gullo G; Bettio D; Zuradelli M; Masci G; Giordano L; Bareggi C; Tomirotti M; Salvini P; Runza L; La Verde N; Santoro A
    Breast; 2013 Apr; 22(2):190-193. PubMed ID: 23473771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
    Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.
    Han HS; Kim JS; Park JH; Jeon YK; Lee KW; Oh DY; Kim JH; Park SY; Im SA; Kim TY; Park IA; Bang YJ
    J Korean Med Sci; 2009 Oct; 24(5):910-7. PubMed ID: 19794992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.
    Köstler WJ; Brodowicz T; Hudelist G; Rudas M; Horvat R; Steger GG; Singer CF; Attems J; Rabitsch W; Fakhrai N; Elandt K; Wiltschke C; Hejna M; Zielinski CC
    J Cancer Res Clin Oncol; 2005 Jul; 131(7):420-8. PubMed ID: 15864644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment.
    Xiao C; Gong Y; Han EY; Gonzalez-Angulo AM; Sneige N
    Ann Oncol; 2011 Jul; 22(7):1547-1553. PubMed ID: 21239403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer.
    Gullo G; Bettio D; Torri V; Masci G; Salvini P; Santoro A
    Invest New Drugs; 2009 Apr; 27(2):179-83. PubMed ID: 18663410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
    Brunello E; Bogina G; Bria E; Vergine M; Zamboni G; Pedron S; Daniele I; Furlanetto J; Carbognin L; Marconi M; Manfrin E; Ibrahim M; Miller K; Tortora G; Molino A; Jasani B; Beccari S; Bonetti F; Chilosi M; Martignoni G; Brunelli M
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1563-8. PubMed ID: 23892410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
    Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
    Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
    Kunitomo K; Inoue S; Ichihara F; Kono K; Fujii H; Matsumoto Y; Ooi A
    Hum Pathol; 2004 Mar; 35(3):379-81. PubMed ID: 15017597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular protocol for HER2/neu analysis in breast carcinoma].
    Artufel MV; Valero AC; Lladó RR; Sagalés NE; Llorca MC; Carazo AM; Cardó CC; Torrus XP
    Clin Transl Oncol; 2005 Dec; 7(11):504-11. PubMed ID: 16373062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
    Latif Z; Watters AD; Dunn I; Grigor K; Underwood MA; Bartlett JM
    Eur J Cancer; 2004 Jan; 40(1):56-63. PubMed ID: 14687790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
    Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.
    Chan A; McGregor SR
    Intern Med J; 2012 Mar; 42(3):267-74. PubMed ID: 21241440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
    Bartsch R; Rottenfusser A; Wenzel C; Dieckmann K; Pluschnig U; Altorjai G; Rudas M; Mader RM; Poetter R; Zielinski CC; Steger GG
    J Neurooncol; 2007 Dec; 85(3):311-7. PubMed ID: 17557136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.